IO Biotech, Inc.

NasdaqGS:IOBT Stock Report

Market Cap: US$60.6m

IO Biotech Management

Management criteria checks 1/4

IO Biotech's CEO is MBZ Zocca, appointed in Jan 2015, has a tenure of 3.25 years. total yearly compensation is $1.65M, comprised of 32.9% salary and 67.1% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $70.35K. The average tenure of the management team and the board of directors is 1.8 years and 3.3 years respectively.

Key information

MBZ Zocca

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage32.9%
CEO tenure10yrs
CEO ownership0.1%
Management average tenure1.8yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation

Dec 17
Here's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Situation

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Jun 12
We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Feb 10
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Jun 15
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Jan 20
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech names new CFO

Oct 13

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Sep 27
We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech GAAP EPS of -$0.64

Aug 11

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Jun 14
We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Feb 25
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has MBZ Zocca's remuneration changed compared to IO Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$90m

Jun 30 2024n/an/a

-US$88m

Mar 31 2024n/an/a

-US$88m

Dec 31 2023US$2mUS$541k

-US$86m

Sep 30 2023n/an/a

-US$80m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$71m

Dec 31 2022US$734kUS$515k

-US$71m

Sep 30 2022n/an/a

-US$74m

Jun 30 2022n/an/a

-US$65m

Mar 31 2022n/an/a

-US$87m

Dec 31 2021US$8mUS$399k

-US$75m

Sep 30 2021n/an/a

-US$56m

Jun 30 2021n/an/a

-US$54m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$409kUS$307k

-US$15m

Compensation vs Market: MBZ's total compensation ($USD1.65M) is above average for companies of similar size in the US market ($USD647.72K).

Compensation vs Earnings: MBZ's compensation has increased whilst the company is unprofitable.

CEO

MBZ Zocca (57 yo)

10yrs

Tenure

US$1,645,088

Compensation

Dr. Mai-Britt Zocca, Ph D, also known as MBZ, was also the Founder and Chief Executive Officer of Onconox ApS since July 2011 until May 2019. She served as Director at Valo Therapeutics Ltd since June 2020...

Leadership Team

NamePositionTenureCompensationOwnership
Mai-Britt Zocca
Founder10yrsUS$1.65m0.12%
$ 70.4k
Devin Smith
Secretary2yrsUS$917.30k0.026%
$ 15.6k
Qasim Ahmad
Chief Medical Officer1.5yrsUS$920.76k0.048%
$ 28.8k
Inge Svane
Founder & Clinical Advisorno datano datano data
Mads Andersen
Co-Founder & Scientific Advisorno datano datano data
Anders Ljungqvist
Founderno datano datano data
Per Straten
Founderno datano datano data
Amy Sullivan
Chief Financial Officer2.3yrsUS$904.15k0.13%
$ 77.9k
Eric Faulkner
Chief Technical Officer1.5yrsno datano data
Daniel Mannix
Senior Vice President of Regulatory Affairs3yrsno datano data
Faical Miyara
Chief Business Officerless than a yearno datano data
Marjan Shamsaei
Senior VP of Commercial Development & Portfolio Leadless than a yearno datano data

1.8yrs

Average Tenure

54.5yo

Average Age

Experienced Management: IOBT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Mai-Britt Zocca
Founder3.3yrsUS$1.65m0.12%
$ 70.4k
Inge Svane
Founder & Clinical Advisorno datano datano data
Mads Andersen
Co-Founder & Scientific Advisorno datano datano data
David Smith
Independent Director2.9yrsUS$124.17k0%
$ 0
K. Hirth
Independent Chairman8.3yrsUS$145.75k0%
$ 0
Christian Elling
Independent Director9.1yrsUS$114.14k0%
$ 0
Kathleen Glaub
Independent Director6.7yrsUS$133.00k0%
$ 0
Alexander Maximiliaan Eggermont
Sr. Clinical Advisor & Member of the Scientific Advisory Boardno datano datano data
Kapil Dhingra
Strategic Advisory Board Memberno datano datano data
Helen Collins
Independent Director1.2yrsUS$52.48k0%
$ 0
Heidi Hunter
Independent Director1.4yrsUS$112.61k0%
$ 0

3.3yrs

Average Tenure

64.5yo

Average Age

Experienced Board: IOBT's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 02:06
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

IO Biotech, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.
Christopher HowertonJefferies LLC
Roger SongJefferies LLC